Baseline inflammation lowers prostate cancer risk on repeat biopsy

Baseline inflammation lowers prostate cancer risk on repeat biopsy
Baseline inflammation lowers prostate cancer risk on repeat biopsy

HealthDay News -- Among men with a negative biopsy for prostate cancer (PCa), acute and chronic inflammation at baseline correlate with a lower PCa risk at repeat two-year biopsy, study findings indicate.

"From a clinical standpoint, inflammation in negative biopsies for PCa may lower the risk of subsequent PCa detection," Daniel M. Moreira, MD, from the Arthur Smith Institute for Urology in New Hyde Park, New York, and colleagues reported in Cancer.

To better understand how baseline prostate inflammation affects subsequent PCa detection, they conducted a retrospective analysis involving 6,238 men aged 50 to 75 years with prostate-specific antigen levels between 2.5 and 10.0 ng/mL and a prior negative biopsy.

The association between inflammation in baseline prostate biopsies and positive two- and four-year repeat biopsies was assessed, with adjustment for baseline covariates.

Acute inflammation, chronic inflammation and both were detected in 1%, 63% and 14% of baseline biopsies, respectively. The overall prevalence of PCa was 14% at the two-year biopsy.

Both acute and chronic inflammation correlated significantly with a lower risk of PCa at the two-year biopsy (acute inflammation: odds ratio 0.65 in univariate and 0.75 on multivariate analysis; chronic inflammation: OR 0.61 on univariate and 0.65 in multivariate analysis).

Only acute inflammation was associated with lower PCa risk at the time of the four-year biopsy.

"Baseline acute and chronic inflammation were both found to be independently associated with a lower PCa risk," the researchers wrote. "From a clinical standpoint, inflammation in negative biopsies for PCa may lower the risk of subsequent PCa detection."

References

  1. Moriera DM et al. Cancer. 2013; doi: 10.1002/cncr.28349.
Loading links....
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Web Exclusives

Sign Up for Free e-newsletters